Posts Tagged ‘Drug Delivery’

Clearside Goes All in for CLS-TA

Clearside Goes All In for CLS-TA

Late last year, when developers of agents that combined anti-platelet derived growth factor with an anti-vascular endothelial growth factor (anti-PDGF/anti-VEGF) to treat wet age-related macular degeneration (AMD) disclosed disappointing trial results, Daniel White, president and CEO of Clearside Biomedical, took notice. At the time, Clearside had just raised $20 million. The Alpharetta, GA, biotech was…

Read More

Eye on Five – January Edition


Alcon Turnaround Has Novartis Exploring Spin-off With its Alcon turnaround plans on track, Novartis AG revealed it is exploring options that include spinning off Alcon or issuing an IPO for the eye-care unit – or even keeping it. Alcon lost $120 million in fourth-quarter 2016 and $132 million for the year versus a profit of…

Read More

After Phase III Disappoints, Inotek Looks to Fixed-Dose Combination

After Phase III Disappoints, Inotek Looks to Fixed-Dose Combination - Eye On Innovation - OIS

As Inotek Pharmaceuticals sifts through the disappointing Phase III top-line results for its lead clinical candidate trabodenoson and the 66% stock price slide that followed, the biopharmaceutical company is nonetheless looking ahead to development of a fixed-dose combination of trabodenoson with latanoprost that is ahead of schedule. In a conference call with analysts the day…

Read More


InnFocus - Companies to Watch - 2015

InnFocus, a Santen company, is pioneering novel surgical solutions for treating glaucoma. The company is positioned to be the first FDA approved minimally invasive stand-alone procedure for mild, moderate, and severe stage open angle Glaucoma, that lowers and sustains IOP under 15 mmHg, and completely eliminates eye drop medications in most patients. The Company is…

Read More

Aerie Ready for Data Release Later This Year

Aerie Ready for Data Release Later This Year - OIS@ASCRS 2016

COO Tom Mitro visits with OISTV to give an update on Aerie’s clinical trial progress. 00:25 – Update on Rhopressa. What’s the good news? 00:39 – Data due on Mercury1 00:57 – Aerie will deliver some scoops at OIS@AAO 01:10 – What’s the goal for ASCRS? 01:25 – Is it challenging to recruit patients for…

Read More

Ocular Therapeutix Waiting for Word from FDA

Ocular Therapeutix expects to hear from the FDA on its PDUFA date of July 24, 2016, on its new drug application for DEXTENZA, its sustained-release dexamethasone intracanalicular depot drug product candidate for treatment of postoperative pain, President and CEO Amar Sawhney, PhD, told the audience at OIS@ASCRS during the Ophthalmology Innovation Showcase. DEXTENZA would be…

Read More

ForSight Reports on Phase II Bimatoprost Ring Results

Phase II results of ForSight Vision5’s bimatoprost ocular ring insert have shown the ring achieves clinically significant reductions in intraocular pressure (IOP) over six months with an acceptable level of safety and tolerability, principal investigator James D. Brandt, MD, reported at OIS@ASCRS. The results were just published online in the journal Ophthalmology. The bimatoprost ring…

Read More

Aerie Looks for Rhopressa NDA in Q3

Aerie Pharmaceuticals has completed all patient visits in two Phase III clinical trials of the Rho kinase inhibitor Rhopressa (netarsudil) 0.02% for treatment of glaucoma and expects to file a New Drug Application with the FDA in the third quarter of this year, president and COO Tom Mitro reported at OIS@ASCRS 2016. Rhopressa lowers intraocular…

Read More

InnFocus Targeting Trabeculectomy

InnFocus’ MicroShunt is the only micro-invasive glaucoma surgery (MIGS) device undergoing a randomized clinical trial that uses trabeculectomy as the comparator. “We want to get to a point where trabeculectomy is really out of the market,” said Russ Trenary, president and CEO. “The stand-alone market is the place to be.” The glaucoma surgical procedure market…

Read More

How Eyenovia Aims to Solve the Problem of Eyedroppers

The natural solution to the problems associated with delivering drops to the front of the eye is inkjet printing, Eyenovia director Curt LaBelle, MD, told the “What’s the Future?” session at OIS@ASCRS 2016 in describing his company’s proprietary drug delivery device. The device looks like a small, white upright torpedo with a button and an…

Read More

Lindstrom Eyes Improvements to Eye Drops

Richard Lindstrom, MD, led the OIS@ASRCS breakfast breakout session “Innovative Alternatives to Drops.” Hear his recap of the problem and the potential solutions that may someday help current and new medicines reach the areas of the eye that need them most. Video Highlights: 00:48 – If everyone used their eye drops they’d be quite safe…

Read More

Outlook for Combination Therapies in Retinal Disease

Outlook for Combination Therapies in Retinal Disease - Eye on Innovation

When Regeneron Pharmaceuticals and Bayer announced their collaboration to develop and commercialize a combination therapy using Regeneron’s vascular endothelial growth factor (VEGF) trap aflibercept (Eylea) and its angiopoietin2 (ANG-2) antibody, nesvacumab, it was the latest in a rash of endeavors – at least seven at last count – to marry different compounds and anti-VEGF agents…

Read More